• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 21, 2018

View Archived Issues

Gorlin for the gold in skin, Leo pledges up to $760M; Pellepharm phase III near

With a "cosmetically elegant" topical therapy, Pellepharm Inc. CEO Sanuj Ravindran told BioWorld that his firm is hoping to exploit the upside of hedgehog inhibition demonstrated so well by Erivedge (vismodegib, Roche Holding AG) while avoiding the downside of a systemic therapy with that mechanism of action in basal cell carcinoma (BCC). Read More

Sobi, Novimmune win FDA approval for primary HLH drug

Just months after Swedish Orphan Biovitrum AB (Sobi) acquired global rights to emapalumab from Swiss developer Novimmune SA in a CHF450 million (US$453 million) deal, the companies have won an on-time FDA approval for the ultra-rare disease therapy. Branded as Gamifant, Sobi will market it for the treatment of pediatric and adult patients with the life-threatening inflammatory condition primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent or progressive disease or intolerance to conventional therapies. It's the first and only FDA-approved therapy for the indication. Read More

Interventional medicine portfolio key to offer as Boston Scientific agrees to buy BTG in $4.2B deal

HAMBURG, Germany – U.S. med-tech giant Boston Scientific Corp. has agreed to buy London-based interventional medical device and acute care pharmaceutical company British Technology Group plc (BTG) in a cash deal valued at £3.3 billion (US$4.2 billion). Read More

Roivant inks $667.5M antibacterials deal with Korea's Intron

Roivant Sciences Ltd. has agreed to pay Gyeonggi-do, South Korea-based Intron Biotechnology Inc. up to $667.5 million for global rights to an experimental therapy for treating infectious diseases caused by antibiotic-resistant staphylococci. The deal, focused on Intron's tonabacase (SAL-200), positions the Basel, Switzerland-based company to begin a phase II trial of SAL-200 in 2019, it said. Read More

Engineered or au naturel, exosomes could address some vexing issues

Want to figure out how to manipulate a cell? See how other cells do it. That, in a nutshell, is the premise underlying the biomedical use of exosomes, small packets of – well, of lots of different things. Read More

Speedy China IND approval as Denovo takes aim at large schizophrenia market

HONG KONG – Denovo Biopharma LLC, a cross-border biotech registered in San Diego and Hangzhou, China, has been granted IND approval by Chinese regulators to conduct international multicenter clinical trials for its neuroscience drug, DB-103 (pomaglumetad). If successful, DB-103 could prove a heavyweight product in the schizophrenia space. Read More

Holiday notice

BioWorld's offices will be closed in observance of Thanksgiving in the U.S. No issue will be published Thursday, Nov. 22, or Friday, Nov. 23. Read More

Appointments and advancements

Magenta Therapeutics Inc., of Cambridge, Mass., appointed Jason Ryan chief operating and financial officer, effective Jan. 1, 2019. Read More

Financings

Xoma Corp., of Emeryville, Calif., said it has begun a rights offering that aims to raise approximately $20 million in gross proceeds. Holders of the company's common stock and series X preferred stock on Nov. 16, are entitled to purchase up to 1.53 million shares of common stock at a subscription price equal to $13 each.  Read More

Other news to note

Bioinvent International AB, of Lund, Sweden, said it has signed a manufacturing agreement with an undisclosed U.S. cell therapy company for the production of cGMP-compliant material to support its clinical development programs. The manufacturing agreement is expected to generate revenue of approximately $1.5 million, mainly in 2019. No other terms of the deal were released. Read More

Clinical data for Nov. 20, 2018

Read More

Regulatory actions for Nov. 20, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 3, 2025.
  • Handshake with DNA, molecules

    Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

    BioWorld
    Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...
  • 3D illustration of pancreatic cancer

    ASCO 2025: Verastem has positive cancer data but stock sags

    BioWorld
    New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe